Adocia shares break through their €3.80 resistance and jump 10.5%

A resistance turned into support, a few cents below the MM200

The stock trades at €4.20 during the session. It is up 10.47% and 43% over one week. The €3.80 level, broken to the upside the previous day and reclaimed during the session, now acts as support. It also corresponds to the highest level of the last 30 sessions.

The share price thus sits clearly above the MM20 (€2.83), but remains 4.4% below the MM200 (€4.39), the next obstacle before the €5.72 resistance. The RSI at 75 reflects the magnitude of the surge.

In the CAC All Shares index, Adocia is among the strongest gainers of the session, while the CAC 40 is up 0.31%. Over one year, however, the stock remains down by more than 52%.

ObesityWeek and cash: the two financial benchmarks of the biotech

Adocia will present new preclinical results on its AdoXLong platform in the form of a poster at ObesityWeek, in Washington, from November 14 to 17. The technology, still at the preclinical stage, aims for a monthly injection. On the financial side, the group reported cash of €8.4 million as of September 30 and revenue of €43 thousand over nine months, according to its accounts published on October 29.

A €7 million financing announced on October 20 and the cost reduction initiated since September push the financing horizon to the first quarter of 2028.

At the time of this publication, the company also cited among its risks its dependence on a $20 million milestone payment, conditional on the authorization of BioChaperone Lispro in China. The Washington poster is the next scheduled event on the calendar, on November 14.